步長製藥(603858.SH):子公司藥品複方腦肽節苷脂注射液退出湖北省醫保目錄
格隆匯12月3日丨步長製藥(603858.SH)公佈,根據湖北省醫療保障局《省醫療保障局關於消化湖北省醫保增補藥品的通知》鄂醫保發﹝2021﹞31號,山東步長製藥股份有限公司控股子公司吉林天成製藥有限公司藥品複方腦肽節苷脂注射液將於2021年12月1日退出湖北省醫保目錄。
複方腦肽節苷脂注射液用於治療腦卒中、老年性痴呆,顱腦損傷、脊髓損傷及創傷性周圍神經損傷,用於治療腦部疾病引起的功能障礙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.